Rosa Luisa Potenza

TL;DR: Overall, the PD rat model used here displays behavioral alterations having face validity with psychiatric symptoms of the pathology and thus appears to be a valuable tool for investigating the neural bases of the early phases of PD.

TL;DR: Results indicate that the tonic activation of A2ARs is required for BDNF‐induced potentiation of synaptic transmission and for sustaining a normal BDNF tone in the hippocampus.

TL;DR: The antagonist Brilliant Blue G (BBG), a blood-brain barrier permeable and safe drug that has already been proven to reduce neuroinflammation in traumatic brain injury, cerebral ischemia-reperfusion, neuropathic pain and experimental autoimmune encephalitis, is used to prove the twofold role of P2X7 in the course of ALS and establish that P2x7 modulation might represent a promising therapeutic strategy by interfering with the neuroinflammatory component of the disease.

TL;DR: In conclusion, A2A antagonists show clear neuroprotective effects in models of brain injury, although their actual therapeutic potential needs to be confirmed in a wider range of doses and in Models of neurodegenerative diseases in which presynaptic and postsynaptic effects play different relative roles.